跳转至内容
Merck
CN

T-905

Thioridazine solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C21H26N2S2
化学文摘社编号:
50-52-2
分子量:
370.57
NACRES:
NA.24
PubChem Substance ID:
329826893
UNSPSC Code:
41116107
MDL number:
MFCD00242875

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

Thioridazine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

InChI

1S/C21H26N2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(24-2)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3

SMILES string

CSc1ccc2Sc3ccccc3N(CCC4CCCCN4C)c2c1

InChI key

KLBQZWRITKRQQV-UHFFFAOYSA-N

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

Quality Level

300

Gene Information

human ... DRD2(1813), DRD3(1814), DRD4(1815), HTR2A(3356), HTR2C(3358)

相关类别

General description

An analytical reference standard applicable for use as starting material in calibrators or controls for thioridazine testing methods by LC-MS/MS or GC-MS. Thioridazine is a treatment for schizophrenia sold under trade names Mellaril, Novoridazine, and Thioril.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes,Central nervous system

存储类别

3 - Flammable liquids

wgk

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

法规信息

危险化学品
此项目有

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Maija Purhonen et al.
Pharmacoepidemiology and drug safety, 21(11), 1227-1231 (2012-09-04)
Thioridazine is a first-generation antipsychotic drug that was withdrawn from the market worldwide in 2005. The outcome of clinically stable schizophrenia patients who used thioridazine before market withdrawal was evaluated. Nationwide registers in Finland were utilized to study thioridazine use
Eduardo Abbate et al.
The Journal of antimicrobial chemotherapy, 67(2), 473-477 (2011-12-03)
Current drug choices to treat extensively drug-resistant (XDR) tuberculosis (TB) are scarce; therefore, information on the safety, tolerability and efficacy of alternative regimens is of utmost importance. The aim of this study was to describe the management, drug adverse effects
Gabriella Spengler et al.
International journal of antimicrobial agents, 39(1), 16-21 (2011-10-11)
Thioridazine (TZ)-induced accumulation of the universal efflux pump substrate ethidium bromide and its subsequent efflux by Salmonella strains with various degrees of overexpressed efflux pumps takes place automatically at pH 7.4, is independent of a metabolic source, is not affected
It is anticipated that as is usually the case, financial motivation will move TZ from its current status “potential anti-MDR/XDR agent,” to one that will cure MDR and XDR TB. Foreword.
Leonard Amaral
Recent patents on anti-infective drug discovery, 6(2), 76-76 (2011-07-30)
Shen-Chieh Chang et al.
Therapeutic drug monitoring, 34(3), 345-348 (2012-05-10)
In this study, the authors studied the effect of thioridazine (TDZ) on the pharmacokinetic profile of quetiapine (QTP) in Taiwanese patients with schizophrenia. Sixteen subjects with schizophrenia were recruited for this study. The authors pretreated 8 patients with TDZ 50
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持